Cipla: Capturing the Global AIDS Drugs Market
ICMR HOME | Case Studies Collection
In 2003, Cipla was one of India's top five pharmaceutical manufacturers, the others being Wockhardt, Ranbaxy, Dr. Reddy's and Nicholas Piramal. Cipla recorded sales of Rs. 15,990.04 million and a net income of Rs 2477.44 million. Over the years, the company had developed strong research and marketing capabilities. Cipla had enjoyed an average annual growth rate of 30.3% from 1999 through 2002, at a time when multinational pharmaceutical companies had grown at only 1%. Although Cipla's primary market was India, the company sold its products worldwide. Cipla's line of more than 400 drugs, included anti-asthmatic, anti-cancer, anti-inflammatory, anti-depressant and anti-AIDS medications.
The subsequent generations of the Hamied family had upheld this tradition. Cipla's Chest Research Foundation was dedicated to research in asthma, Chronic obstructive pulmonary disease (COPD), allergic airways diseases and other respiratory ailments. The Foundation conducted clinical research, bioequivalence studies and CME (continuing medical education) programmes for the medical profession. The Cipla Foundation's Palliative Care Centre for cancer patients in Pune provided comfort and solace to over 2800 terminally ill patients.
Case Studies Links:-
Short Case Studies,
Simplified Case Studies.
Other Case Studies:- Multimedia Case Studies, Cases in Other Languages.
Business Reports Link:- Business Reports.
Books:- Textbooks, Work Books, Case Study Volumes.
|Business Environment||Business Ethics||Business Reports||Business Strategy|
|Corporate Governance||Economics||Enterprise Risk Management||Finance|
|HRM||Innovation||Insurance||IT and Systems|
|Leadership and Entrepreneurship||Marketing||Miscellaneous||Operations|
|Project Management||Short Case Studies||Cases in other Languages||Free Case Studies|